Researchers at the Institute for Clinical and Economic Review (ICER), Aetion, and the University of Washington collaborated to determine how observational real world evidence (RWE) impacted ICER’s 2018 report on hereditary angioedema therapies. ICER recommends substantial price discounts ranging for Takhzyro, Haegarda, and Cinryze, ranging from 53% to 75%.
ICER’s Senior Vice President of Health Economics Dr. Jon Campbell remarks, “De-identified claims data suggest that patients initiating prophylaxis therapy in the real world had fewer baseline attacks than that of individuals who participated in the clinical trials. As a result, all three assessed therapies require even larger price discounts to reach common thresholds for cost-effectiveness than what our models had originally projected in 2018.” Read more here.
(Source: ICER, 8/24/21)